Abstract:Background Angiosarcoma is a histologically and molecularly heterogeneous vascular neoplasm with aggressive clinical behavior. Emerging data suggests that immune checkpoint blockade (ICB) is efficacious against some angiosarcomas, particularly cutaneous angiosarcoma of the head and neck (CHN). Methods Patients with histologically confirmed angiosarcoma treated with ICB-based therapy at a comprehensive cancer center were retrospectively identified. Clinical characteristics and the results of targeted exome sequencing, transcriptome sequencing, and immunohistochemistry analyses were examined for correlation with clinical benefit. Durable clinical benefit was defined as a progression-free survival (PFS) of ≥16 weeks. Results For the 35 patients included in the analyses, median PFS and median overall survival (OS) from the time of first ICB-based treatment were 11.9 (95% CI 7.4 to 31.9) and 42.5 (95% CI 19.6 to 114.2) weeks, respectively. Thirteen patients (37%) had PFS ≥16 weeks. Clinical factors associated with longer PFS and longer OS in multivariate analyses were ICB plus other therapy regimens, CHN disease, and white race. Three of 10 patients with CHN angiosarcoma evaluable for tumor mutational burden (TMB) had a TMB ≥10. Five of six patients with CHN angiosarcoma evaluable for mutational signature analysis had a dominant mutational signature associated with ultraviolet (UV) light. No individual gene or genomic pathway was significantly associated with PFS or OS; neither were TMB or UV signature status. Analyses of whole transcriptomes from nine patient tumor samples found upregulation of angiogenesis, inflammatory response, and KRAS signaling pathways, among others, in patients with PFS ≥16 weeks, as well as higher levels of cytotoxic T cells, dendritic cells, and natural killer cells. Patients with PFS <16 weeks had higher numbers of cancer-associated fibroblasts. Immunohistochemistry findings for 12 patients with baseline samples available suggest that neither PD-L1 expression nor presence of tumor-infiltrating lymphocytes at baseline appears necessary for a response to ICB-based therapy. Conclusions ICB-based therapy benefits only a subset of angiosarcoma patients. Patients with CHN angiosarcoma are more likely to have PFS ≥16 weeks, a dominant UV mutational signature, and higher TMB than angiosarcomas arising from other primary sites. However, clinical benefit was seen in other angiosarcomas also and was not restricted to tumors with a high TMB, a dominant UV signature, PD-L1 expression, or presence of tumor infiltrating lymphocytes at baseline.

Angiosarcoma: clinical outcomes and prognostic factors, a single-center analysis

Clinicopathological Features and Prognostic Factors in Angiosarcoma: A Retrospective Analysis of 200 Patients from A Single Chinese Medical Institute

Antiprogrammed Cell Death Protein 1 Immunotherapy for Angiosarcoma with High Programmed Death-Ligand 1 Expression: a Case Report

A Population-Based Long-Term Follow-Up of Soft Tissue Angiosarcomas: Characteristics, Treatment Outcomes, and Prognostic Factors

Therapeutic Outcomes in 691 Angiosarcomas of the Head and Neck—A Retrospective SEER Study

Epidemiology, tumor characteristics and survival in patients with angiosarcoma in the United States: a population-based study of 4537 cases

Treatment of angiosarcoma at a single institution

Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis

Clinical outcomes in primary scalp angiosarcoma.

Primary and secondary breast angiosarcoma: single center report and a meta-analysis

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study

Hepatic Angiosarcoma: A Multi-institutional, International Experience with 44 Cases

Cutaneous Angiosarcoma Subtypes: A Quantitative Systematic Review of Demographics, Treatments, and Outcomes Within Published Patient-Level Cases

The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium

Outcome improvement with chemotherapy and radiotherapy in primary, localized, radiation-associated angiosarcoma of the breast region: a retrospective case series analysis

Gliosarcoma: A Multi‐Institutional Analysis on Clinical Outcomes and Prognostic Factors

Long-term Survival of a Patient with Scalp Angiosarcoma and Multiple Metastases Treated Using Combination Therapy: A Case Report.

Risk Stratification with Sarculator and MSKCC in Patients with Primary and Secondary Angiosarcoma

Prognostic significance of positive surgical margins for scalp angiosarcoma

Current and Future Directions for Angiosarcoma Therapy

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center